vspВопросы современной педиатрииCurrent Pediatrics1682-55271682-5535Издательство «ПедиатрЪ»10.15690/vsp.v12i5.795vsp-277Research ArticleНЕПРЕРЫВНОЕ ПРОФЕССИОНАЛЬНОЕ ОБРАЗОВАНИЕPROFESSIONAL DEVELOPMENTАЛГОРИТМ ПОСИНДРОМНОЙ КОМПЛЕКСНОЙ ТЕРАПИИ ПРИ МУКОВИСЦИДОЗЕ У ДЕТЕЙ: СОВРЕМЕННЫЙ ПОДХОДTHE ALGORITHM OF COMPLEX SYNDROME-ORIENTED THERAPY IN CHILDREN WITH CYSTIC FIBROSIS: A MODERN APPROACHГориноваЮ. В.GorinovaYu. V.

Gorinova Yuliya Viktorovna, Candidate of Medical Sciences, Senior Researcher at the Department of Pulmonology and Allergology

oisimonova@mail.ruСимоноваО. И.SimonovaO. I.oisimonova@mail.ruТомиловаА. Ю.TomilovaA. Yu.oisimonova@mail.ruРославцеваЕ. А.RoslavtsevaE. A.oisimonova@mail.ruНаучный Центр здоровья детей РАМН, МоскваРоссияScientific Centre of Children Health of RAMS, MoscowRussian FederationНаучный Центр здоровья детей РАМН, Москва; Первый Московский государственный медицинский университет им. И.М. СеченоваРоссияScientific Centre of Children Health of RAMS, Moscow; I.M. Sechenov First Moscow State Medical UniversityRussian FederationНаучный Центр здоровья детей РАМН, Москва,РоссияScientific Centre of Children Health of RAMS, MoscowRussian Federation201319092013125Вопросы современной педиатрии3038Copyright © Горинова Ю.В., Симонова О.И., Томилова А.Ю., Рославцева Е.А., 20132013Горинова Ю.В., Симонова О.И., Томилова А.Ю., Рославцева Е.А.Gorinova Y.V., Simonova O.I., Tomilova A.Y., Roslavtseva E.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://vsp.spr-journal.ru/jour/article/view/277

Муковисцидоз — это полиорганная патология, лечение которой требует комплексного (сочетание медикаментозных и немедикаментозных методов) подхода. Специализированная помощь в центрах муковисцидоза позволяет улучшить показатели выживаемости и качества жизни больных. В статье приведена информация об основных препаратах, применяемых при муковисцидозе в настоящее время. Описаны особенности использования дорназы альфа у детей разного возраста, представлены данные об эффектах препарата: мощном муколитическом, противовоспалительном и антибактериальном действии. Обоснована целесообразность включения препарата в состав базисной терапии с профилактической и лечебной целью сразу при постановке диагноза: «Муковисцидоз». Показано, что при хронической синегнойной инфекции стабилизовать состояние больного муковисцидозом возможно, используя постоянные ингаляций растворов тобрамицина или колимистата натрия, а также с помощью инновационной порошковой лекарственной формы тобрамицина. Отмечено, что при муковисцидозе эффективным ферментом поджелудочной железы может быть только лекарственная форма панкреатина в виде минимикросфер. Впервые авторами предложен алгоритм комплексного лечения заболевания в зависимости от его симптомов и осложнений.

Cystic fibrosis is a disease, which involves multiple organs and systems, and treatment of this disorder requires a complex approach (combination of medicinal and non-medicinal methods). Specialized medical care in centers for cystic fibrosis treatment allows to improve the patients’ rates of survivability and quality of life. This article contains information on the main drugs used nowadays in cystic fibrosis therapy. The authors describe the special characteristics of dornase alfa use in children of various age groups and detail the effects of this drug: powerful mucolytic, anti-inflammatory and antibacterial actions. The rationality of including of this drug into the basic therapy both with preventative and medicinal aims as soon as a patient is diagnosed with cystic fibrosis is substantiated. It is shown, that in cases of chronic Pseudomonas aeruginosa infections a patient’s condition can be stabilized with the means of continual tobramycin or sodium colistimethate inhalations, as well as the new powder form of tobramycin. It was noted, that in cystic fibrosis pancreatic enzyme can be effective only in forms of minimicrospheres. For the first time the new algorithm of complex treatment of this disease according to the symptoms and complications was offered by the authors.

 

детимуковисцидозалгоритм комплексной терапиидорназа альфаchildrencystic fibrosisalgorithm of complex treatmentdornase alfaReferencesDodge J. A., Lewis P. A., Stanton M. et al. Cystic fibrosis mortality and survival in the United Kingdom, 1947 to 2003. Eur. Respir. J. 2006; 20: 4–51.Dodge J. A., Lewis P. A., Stanton M. et al. Cystic fibrosis mortality and survival in the United Kingdom, 1947 to 2003. Eur. Respir. J. 2006; 20: 4–51.Krasovskiy S. A., Chernyak A. V., Amelina E. L., NiKon’ova V. S., Voronkova A.Yu., Samoylenko V. A., Naumenko Zh. K., Kashir skaya N.Yu., Kapranov N. I., Sherman V. D., Shabolova L. A., Chistyakova V. P., Simonova O. I., Semykin S.Yu., Gorinova Yu. V., Avakyan L. V., Petrova P. N., Kusova Z. A., Usachyova M. V., Samsono va M. V. et al. Dinamika Vyzhivaemosti Bol'nykh Mukovistsidozom v Moskve i Moskovskoy Oblasti 1992–2001 i 2002–2011 gg [Dynamics of Survival in Patients with Cystic Fibrosis in Moscow and the Moscow Region in 1992–2001 and 2002–2011]. Pul'monologiya [Pulmonology]. 2012; 3:79–87.Krasovskiy S. A., Chernyak A. V., Amelina E. L., NiKon’ova V. S., Voronkova A.Yu., Samoylenko V. A., Naumenko Zh. K., Kashir skaya N.Yu., Kapranov N. I., Sherman V. D., Shabolova L. A., Chistyakova V. P., Simonova O. I., Semykin S.Yu., Gorinova Yu. V., Avakyan L. V., Petrova P. N., Kusova Z. A., Usachyova M. V., Samsono va M. V. et al. Dinamika Vyzhivaemosti Bol'nykh Mukovistsidozom v Moskve i Moskovskoy Oblasti 1992–2001 i 2002–2011 gg [Dynamics of Survival in Patients with Cystic Fibrosis in Moscow and the Moscow Region in 1992–2001 and 2002–2011]. Pul'monologiya [Pulmonology]. 2012; 3:79–87.Cystic Fibrosis Mutation Database. URL: http:// www.genet. sickkids.on.ca/cftrCystic Fibrosis Mutation Database. URL: http:// www.genet. sickkids.on.ca/cftrSimonova O. I. Vozmozhnosti Primeneniya Dornazy Al'fa v Pediatricheskoy Praktike [Possible Applications of Dornase Alfa in Pediatric Practice]. Voprosy sovremennoy pediatrii [Current Pediatrics]. 2011; 10 (4): 145–152.Simonova O. I. Vozmozhnosti Primeneniya Dornazy Al'fa v Pediatricheskoy Praktike [Possible Applications of Dornase Alfa in Pediatric Practice]. Voprosy sovremennoy pediatrii [Current Pediatrics]. 2011; 10 (4): 145–152.Simonova O. I. Kompleksnaya Terapiya Detey s Mukovistsidozom: Rekomendatsii dlya Pediatra [Combined Therapy of Children with Cystic Fibrosis: Recommendations for Pediatricians]. Pediatriches kaya farmakologiya [Pediatric Pharmacology]. 2006; 3 (6): 44–50.Simonova O. I. Kompleksnaya Terapiya Detey s Mukovistsidozom: Rekomendatsii dlya Pediatra [Combined Therapy of Children with Cystic Fibrosis: Recommendations for Pediatricians]. Pediatriches kaya farmakologiya [Pediatric Pharmacology]. 2006; 3 (6): 44–50.Amelina E. L., Anaev E.Kh, Krasovskiy S. A., Romanova L. K., Simonova O. I., Chernyaev A. L., Chikina S.Yu. Mukoaktivnaya Terapiya [Mucoactive Therapy]. Edited by A. G. Chuchalin, A. S. Belevskiy. Moscow, Atmosfera Publ., 2006. 104–124 p.Amelina E. L., Anaev E.Kh, Krasovskiy S. A., Romanova L. K., Simonova O. I., Chernyaev A. L., Chikina S.Yu. Mukoaktivnaya Terapiya [Mucoactive Therapy]. Edited by A. G. Chuchalin, A. S. Belevskiy. Moscow, Atmosfera Publ., 2006. 104–124 p.Khrushchev S. V., Simonova O. I. Fizicheskaya Kul'tura Detey s Zabolevaniyami Organov Dykhaniya: Uchebnoe Posobie dlya Studentov Vysshikh Uchebnykh Zavedeniy [Physical Education of Children with Respiratory Diseases: A Textbook for University Students]. Moscow, Akademiya Publ., 2006. 304 p.Khrushchev S. V., Simonova O. I. Fizicheskaya Kul'tura Detey s Zabolevaniyami Organov Dykhaniya: Uchebnoe Posobie dlya Studentov Vysshikh Uchebnykh Zavedeniy [Physical Education of Children with Respiratory Diseases: A Textbook for University Students]. Moscow, Akademiya Publ., 2006. 304 p.Simonova O. I., Roslavtseva E. A. Osobennosti Zamestitel'noy Fermentoterapii pri Mukovistsidoze u Detey: Preimushchestva Vysok otekhnologichnykh Fermentnykh Preparatov [Features of Substitute Enzyme Therapy at Cystic Fibrosis in Children: Advantages of HighTech Enzymatic Products]. Voprosy sovremennoy pediatrii [Current Pediatrics]. 2011; 10 (5): 152–156.Simonova O. I., Roslavtseva E. A. Osobennosti Zamestitel'noy Fermentoterapii pri Mukovistsidoze u Detey: Preimushchestva Vysok otekhnologichnykh Fermentnykh Preparatov [Features of Substitute Enzyme Therapy at Cystic Fibrosis in Children: Advantages of HighTech Enzymatic Products]. Voprosy sovremennoy pediatrii [Current Pediatrics]. 2011; 10 (5): 152–156.Kashirskaya N.Yu., Kapranov N. I. Korrektsiya Ekzokrinnoy Nedostatochnosti Podzheludochnoy Zhelezy Mikrogranulirovannymi Pankreaticheskimi Fermentnymi Preparatami u Bol'nykh Mukovistsidozom [Correction of Exocrine Pancreatic Insufficiency Using Microgranulated Pancreatic Enzyme Preparations in Cystic Fibrosis Patients]. Voprosy sovremennoy pediatrii [Current Pediatrics]. 2002; 1 (5): 74–78.Kashirskaya N.Yu., Kapranov N. I. Korrektsiya Ekzokrinnoy Nedostatochnosti Podzheludochnoy Zhelezy Mikrogranulirovannymi Pankreaticheskimi Fermentnymi Preparatami u Bol'nykh Mukovistsidozom [Correction of Exocrine Pancreatic Insufficiency Using Microgranulated Pancreatic Enzyme Preparations in Cystic Fibrosis Patients]. Voprosy sovremennoy pediatrii [Current Pediatrics]. 2002; 1 (5): 74–78.Baranov A. A., Borovik T. E., Roslavtseva E. A. et al. Dietoterapiya v Kompleksnom Lechenii Mukovistsidoz: Posobie dlya Vrachey [Diet Therapy in Treatment of Cystic Fibrosis: A Manual for Physicians]. As part of the subprogramme «Healthy Child» within the Federal Target Program «Children of Russia» MZiSR, Federal Agency for Health and Social Development, RAMS. Moscow, 2005. 94 p.Baranov A. A., Borovik T. E., Roslavtseva E. A. et al. Dietoterapiya v Kompleksnom Lechenii Mukovistsidoz: Posobie dlya Vrachey [Diet Therapy in Treatment of Cystic Fibrosis: A Manual for Physicians]. As part of the subprogramme «Healthy Child» within the Federal Target Program «Children of Russia» MZiSR, Federal Agency for Health and Social Development, RAMS. Moscow, 2005. 94 p.Roslavtseva E. A., Borovik T. E., Simonova O. I., Ignatova A. S. Osobennosti Pitaniya Detey Rannego Vozrasta, Bol'nykh Mukovistsidozom [Peculiarities of Feeding Infants with Cystic Fibrosis]. Voprosy sovremennoy pediatrii [Current Pediatrics]. 2010; 9 (1): 162–167.Roslavtseva E. A., Borovik T. E., Simonova O. I., Ignatova A. S. Osobennosti Pitaniya Detey Rannego Vozrasta, Bol'nykh Mukovistsidozom [Peculiarities of Feeding Infants with Cystic Fibrosis]. Voprosy sovremennoy pediatrii [Current Pediatrics]. 2010; 9 (1): 162–167.Lohr J. M., Hummel F. M., Pirilis K. T. et al. Properties of different pancreatin preparations used in pancreatic exocrine insufficiency. Eur. J. Gastroenterol. Hepatol. 2009; 21: 1024–1031.Lohr J. M., Hummel F. M., Pirilis K. T. et al. Properties of different pancreatin preparations used in pancreatic exocrine insufficiency. Eur. J. Gastroenterol. Hepatol. 2009; 21: 1024–1031.Kerem E., Conway S., Elborn S., Heijerman H. Standards of care for patients with cystic fibrosis: A European consensus. J. Cyst. Fibrosis. 2005; 4: 7–26.Kerem E., Conway S., Elborn S., Heijerman H. Standards of care for patients with cystic fibrosis: A European consensus. J. Cyst. Fibrosis. 2005; 4: 7–26.Kapranov N. I., Kashirskaya N.Yu., Petrova N. V. Mukovistsidoz. Dostizheniya i Problemy na Sovremennom Etape [Cystic Fibrosis. Achievements and Challenges at the Present Stage]. Meditsinskaya genetika [Medical Genetics]. 2004; 9: 398–412.Kapranov N. I., Kashirskaya N.Yu., Petrova N. V. Mukovistsidoz. Dostizheniya i Problemy na Sovremennom Etape [Cystic Fibrosis. Achievements and Challenges at the Present Stage]. Meditsinskaya genetika [Medical Genetics]. 2004; 9: 398–412.Simonova O. I., Lukina O. F. Dornaza Al'fa v Rossii: 15 Let Spustya. Effektivnost' Preparata v Bazisnoy Terapii u Detey s Mukovistsidozom [Dornase Alfa in Russia: 15 Years Later. Medication Effectiveness in the Basic Therapy in Children with Cystic Fibrosis]. Voprosy sovremennoy pediatrii [Current Pediatrics]. 2012; 11 (2): 132–139.Simonova O. I., Lukina O. F. Dornaza Al'fa v Rossii: 15 Let Spustya. Effektivnost' Preparata v Bazisnoy Terapii u Detey s Mukovistsidozom [Dornase Alfa in Russia: 15 Years Later. Medication Effectiveness in the Basic Therapy in Children with Cystic Fibrosis]. Voprosy sovremennoy pediatrii [Current Pediatrics]. 2012; 11 (2): 132–139.Shah P., Conway S., Scott S., Hodson M. et al. A case-controlled study with Dornase Alfa to evaluate impact on disease progression over a 4 year period. J. Respiration. 2001; 68: 160–164.Shah P., Conway S., Scott S., Hodson M. et al. A case-controlled study with Dornase Alfa to evaluate impact on disease progression over a 4 year period. J. Respiration. 2001; 68: 160–164.Fushs H. J., Borowitz D. S., Christiansen D. H. et al. Effect of aerolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N. Engl. J. Med. 1994; 331: 637–642.Fushs H. J., Borowitz D. S., Christiansen D. H. et al. Effect of aerolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N. Engl. J. Med. 1994; 331: 637–642.Shak S., Capon D. J., Hellmiss R. et al. Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum. Proceedings of the National Academy of Science (USA). 1990; 87: 9188–9192.Shak S., Capon D. J., Hellmiss R. et al. Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum. Proceedings of the National Academy of Science (USA). 1990; 87: 9188–9192.Voronkova A.Yu. Klinicheskaya Effektivnost' i Bezopasnost' Dornazy Al'fa v Lechenii Bronkholegochnogo Protsessa u Detey, Bol'nykh Mukovistsidozom [Clinical Efficacy and Safety of Dornase Alfa in the Treatment of Bronchopulmonary Process in Children with Cystic Fibrosis]. Avtoreferat-dissertatsiya kandidata meditsinskikh nauk [Autoabstract-thesis of Candidate of Medical Sciences]. Moscow, 2004. 23 p.Voronkova A.Yu. Klinicheskaya Effektivnost' i Bezopasnost' Dornazy Al'fa v Lechenii Bronkholegochnogo Protsessa u Detey, Bol'nykh Mukovistsidozom [Clinical Efficacy and Safety of Dornase Alfa in the Treatment of Bronchopulmonary Process in Children with Cystic Fibrosis]. Avtoreferat-dissertatsiya kandidata meditsinskikh nauk [Autoabstract-thesis of Candidate of Medical Sciences]. Moscow, 2004. 23 p.Kapranov N. I., Gembitskaya T. E., Simonova O. I., Amelina E. L., Kovalyova L. F., Shabolova L. A., Kashirskaya N.Yu., Faustova M. Opyt Dlitel'nogo Primeneniya Novogo Mukoliticheskogo Preparata “Pul'mozim” u Bol'nykh Mukovistsidozom [Experience of Long Application of the New Mucolytic Drug “Pulmozyme” in Cystic Fibrosis Patients]. Terapevticheskiy arkhiv [Therapeutic Archive]. 2001; 1: 55.Kapranov N. I., Gembitskaya T. E., Simonova O. I., Amelina E. L., Kovalyova L. F., Shabolova L. A., Kashirskaya N.Yu., Faustova M. Opyt Dlitel'nogo Primeneniya Novogo Mukoliticheskogo Preparata “Pul'mozim” u Bol'nykh Mukovistsidozom [Experience of Long Application of the New Mucolytic Drug “Pulmozyme” in Cystic Fibrosis Patients]. Terapevticheskiy arkhiv [Therapeutic Archive]. 2001; 1: 55.Robinson T. E., Goris M. L., Zhu H. J., Chen X., Bhise P., Sheikh F., Moss R. B. Dornase Alfa reduces air trapping in children with mild cystic fibrosis lung disease. Chest. 2005; 128 (4): 2327–2335.Robinson T. E., Goris M. L., Zhu H. J., Chen X., Bhise P., Sheikh F., Moss R. B. Dornase Alfa reduces air trapping in children with mild cystic fibrosis lung disease. Chest. 2005; 128 (4): 2327–2335.Simmonds G. Improved survival at low lung function in cystic fibrosis: cohort study from 1990 to 2007. BMJ. 2011; 324: 1008.Simmonds G. Improved survival at low lung function in cystic fibrosis: cohort study from 1990 to 2007. BMJ. 2011; 324: 1008.Matsui H., Grubb BR., Tarran R. et al. Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of CF airways disease. Cell. 1998; 95: 1005–1015.Matsui H., Grubb BR., Tarran R. et al. Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of CF airways disease. Cell. 1998; 95: 1005–1015.Worlitzsch D., Tarran R., Ulrich M. et al. Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of CF patients. Clin. Invest. 2002; 109: 317–325.Worlitzsch D., Tarran R., Ulrich M. et al. Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of CF patients. Clin. Invest. 2002; 109: 317–325.Konstan M. W., Berger M. Current understanding of the inflammatory process in CF: onset and etiology. Pediatr. Pulmonol. 1997; 24: 137–142Konstan M. W., Berger M. Current understanding of the inflammatory process in CF: onset and etiology. Pediatr. Pulmonol. 1997; 24: 137–142Simonova O. I., Solovyova Yu. V., Vasilyeva E. M. Mukolitik s Protivovospalitel'nymi Svoystvami dlya Detey s Mukovistsidozom: Dornaza Alfa [Mucolytic with Anti-Inflammatory Properties for Children with Cystic Fibrosis: Dornase Alfa]. Pediatricheskaya farmakologiya [Pediatric Pharmacology]. 2012; 9 (6): 85–90.Simonova O. I., Solovyova Yu. V., Vasilyeva E. M. Mukolitik s Protivovospalitel'nymi Svoystvami dlya Detey s Mukovistsidozom: Dornaza Alfa [Mucolytic with Anti-Inflammatory Properties for Children with Cystic Fibrosis: Dornase Alfa]. Pediatricheskaya farmakologiya [Pediatric Pharmacology]. 2012; 9 (6): 85–90.Kapranov N. I., Kashirskaya N.Yu. Mukovistsidoz. Sovremennye Dostizheniya i Aktual'nye Problemy. Metodologicheskie Reko mendatsii [Cystic Fibrosis. Modern Developments and Topical Issues. Methodological Recommendations]. Moscow, 2011.Kapranov N. I., Kashirskaya N.Yu. Mukovistsidoz. Sovremennye Dostizheniya i Aktual'nye Problemy. Metodologicheskie Reko mendatsii [Cystic Fibrosis. Modern Developments and Topical Issues. Methodological Recommendations]. Moscow, 2011.Donaldson S. H., Bennett W. D., Zeman K. L., Knowles M. R., Tarran R., Boucher R. C. Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N. Engl. J. Med. 2006; 354 (3): 241.Donaldson S. H., Bennett W. D., Zeman K. L., Knowles M. R., Tarran R., Boucher R. C. Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N. Engl. J. Med. 2006; 354 (3): 241.Suri R., Metcalfe C., Lees B., Grieve R., Flather M., Normand C., Thompson S., Bush A., Wallis C. Comparison of hypertonic saline and alternate-day or daily recombinant human deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet. 2001; 358 (9290): 1316.Suri R., Metcalfe C., Lees B., Grieve R., Flather M., Normand C., Thompson S., Bush A., Wallis C. Comparison of hypertonic saline and alternate-day or daily recombinant human deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet. 2001; 358 (9290): 1316.Wark P., McDonald V. M. Nebulised hypertonic saline for cystic fibrosis. Cochr. Database Syst. Rev. 2009: CD001506.Wark P., McDonald V. M. Nebulised hypertonic saline for cystic fibrosis. Cochr. Database Syst. Rev. 2009: CD001506.Elkins M., Dentice R. Timing of hypertonic saline inhalation for cystic fibrosis. Cochr. Database Syst. Rev. 2012; 2: CD008816.Elkins M., Dentice R. Timing of hypertonic saline inhalation for cystic fibrosis. Cochr. Database Syst. Rev. 2012; 2: CD008816.Rosenfeld M., Ratjen F., Brumback L., Daniel S., Rowbotham R., McNamara S., Johnson R., Kronmal R., Davis S. D. Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial. ISIS Study Group. JAMA. 2012; 307 (21): 2269–2277.Rosenfeld M., Ratjen F., Brumback L., Daniel S., Rowbotham R., McNamara S., Johnson R., Kronmal R., Davis S. D. Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial. ISIS Study Group. JAMA. 2012; 307 (21): 2269–2277.Doring G., Conway S., Heijerman H. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur. Respir. J. 2000; 16: 749–767.Doring G., Conway S., Heijerman H. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur. Respir. J. 2000; 16: 749–767.Konstan М. et al. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients. EAGER Trial J. Cyst. Fibrosis. 2011; 10: 54–61.Konstan М. et al. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients. EAGER Trial J. Cyst. Fibrosis. 2011; 10: 54–61.Konstan М. et al. Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis. EVOLVE Trial Pediatr. Pulmonol. 2011; 46: 230–238.Konstan М. et al. Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis. EVOLVE Trial Pediatr. Pulmonol. 2011; 46: 230–238.Adeboyeku D., Scott S., Hodson M. E. Open follow-up study of tobramycin nebuliser solution and colistin in patients with cystic fibrosis. J. Cyst. Fibrosis. 2006; 5: 261.Adeboyeku D., Scott S., Hodson M. E. Open follow-up study of tobramycin nebuliser solution and colistin in patients with cystic fibrosis. J. Cyst. Fibrosis. 2006; 5: 261.Hodson M. E., Gallagher C. G., Govan J. R. A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis. Eur. Respir. J. 2002; 20: 658.Hodson M. E., Gallagher C. G., Govan J. R. A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis. Eur. Respir. J. 2002; 20: 658.Sermet-Gaudelus I. Ivacaftor treatment in patients with cystic fibro sis and the G551D-CFTR mutation. Eur. Respir. Rev. 2013; 127: 66–71.Sermet-Gaudelus I. Ivacaftor treatment in patients with cystic fibro sis and the G551D-CFTR mutation. Eur. Respir. Rev. 2013; 127: 66–71.

The authors declare that there are no conflicts of interest present.